Source link : https://www.newshealth.biz/health-news/monoclonal-antibodies-make-headway-in-sjogren-treatment/
VIENNA — Nipocalimab, iscalimab, and tibulizumab, but not lusvertikimab, appear to be promising new agents for Sjögren disease that warrant further investigation, suggest the results of four separate early clinical trials reported at the recent European Alliance of Associations for Rheumatology (EULAR) 2024 Annual Meeting. This is potentially good news for patients, as discovering new […]
Author : News Health
Publish date : 2024-08-05 09:44:44
Copyright for syndicated content belongs to the linked Source.